Present and Future Post-marketing Drug Safety Assessment in Japan: A PMDA Perspective

Therapeutic Innovation and Regulatory Science · Published 2026-04-24 · DOI 10.1007/s43441-026-00964-6

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s43441-026-00964-6

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Impacts of Random and Fixed Effect Models on Type I and Type II Errors in Bioequivalence Hypotheses in Crossover Trial Designs: A Comprehensive Simulation Study · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Trends and Regulatory Insights on Illicit Pharmaceutical and Cosmetic Imports: Evidence from Malaysia’s Operation Pangea 2020–2023 · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• How Digital Health Technologies have been Used to Support Regulatory Drug Approval · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Feasibility of a Monthly Morphine Milligram Equivalent Metric for Opioid Surveillance Using the National Claims Database of Japan: A Repeated Cross-Sectional Study in a Low-Consumption Setting · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Measuring Centralized Patient Outreach Recruitment Strategies and their Costs in Clinical Trials · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Arbitrated Indirect Treatment Comparisons · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now? · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Accelerating Global Access for Indication Extension Through Regulatory Reliance Pilot: The First Indication Extension Pilot in Oncology · Therapeutic Innovation and Regulatory Science · 2026 · Same journal
• Current Status and Construction Requirements of Drug Clinical Trial Institutions in Sichuan Province in China · Therapeutic Innovation and Regulatory Science · 2026 · Same journal